Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nebivolol: a review.

John Cockcroft1

  • 1Wales Heart Research Institute, University Hospital Health Park, South Wales. CockcroftJR@cardiff.ac.uk

Expert Opinion on Pharmacotherapy
|April 23, 2004
PubMed
Summary
This summary is machine-generated.

Nebivolol, a unique beta-blocker, lowers blood pressure by improving blood flow and preserving cardiac output. It offers comparable or better outcomes and safety than other antihypertensives, potentially reducing cardiovascular risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GOLD 2026 COPD ABE assessment tool to identify individuals at high risk in a UK multicentre COPD cohort (ERICA).

BMJ open respiratory research·2026
Same author

Single-beat right ventricular-pulmonary artery coupling and residual heart failure in patients with a HeartMate 3 left ventricular assist device.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Modest Blood Pressure Increase with Age in Adults with Down's Syndrome.

The New England journal of medicine·2025
Same author

Is biomechanical loading reduced in individuals with unilateral transtibial amputation during fast-paced walking when using different ankle/foot prostheses? A pragmatic randomized controlled trial.

Prosthetics and orthotics international·2024
Same author

Noninvasive Estimation of Blood Pressure in HeartMate 3 Patients.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2023
Same author

Twenty-four-hour blood pressure and heart rate variability are reduced in patients on left ventricular assist device support.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2022

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Nebivolol is a beta-adrenergic blocker with vasodilating properties.
  • Its unique mechanism involves the L-arginine nitric oxide (NO) pathway, differentiating it from other beta-blockers.

Purpose of the Study:

  • To elucidate the hemodynamic profile and clinical effects of nebivolol.
  • To compare nebivolol's efficacy and safety against other antihypertensive agents.

Main Methods:

  • Comparative analysis of nebivolol's hemodynamic effects.
  • Evaluation of treatment response rates and adverse event profiles.

Main Results:

  • Nebivolol reduces peripheral resistance, increases stroke volume, and preserves cardiac output.
  • Higher response rates and comparable or lower adverse event incidence were observed with nebivolol.

Related Experiment Videos

Conclusions:

  • Nebivolol's vasodilating action, mediated by NO, contributes to its blood pressure-lowering effect.
  • By improving endothelial function and reducing arterial stiffness, nebivolol may decrease cardiovascular risk.